Annals of Gastroenterology最新文献_第4页

Diverticulosis and neoplastic lesions in screening colonoscopy: a large, multicenter study. 结肠镜筛查中的憩室病和肿瘤病变：一项大型多中心研究。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.20524/aog.2024.0928

Paolo Fedeli, Monica Masotti, Chiara Marzano, Angelo Dezi, Giuseppe Scaccianone, Elisabetta Martinelli, Lucia Montenegro, Maurizio Giovannone, Alessandra Zannella, Alessandro Gigliozzi, Alessandro Azzarone, Roberto Bringiotti, Costantino Zampaletta, Maria Carlotta Sacchi, Lorenzo Ridola, Alessandra Spagnoli, Sabrina Berardi, Angelo Zullo

{"title":"Diverticulosis and neoplastic lesions in screening colonoscopy: a large, multicenter study.","authors":"Paolo Fedeli, Monica Masotti, Chiara Marzano, Angelo Dezi, Giuseppe Scaccianone, Elisabetta Martinelli, Lucia Montenegro, Maurizio Giovannone, Alessandra Zannella, Alessandro Gigliozzi, Alessandro Azzarone, Roberto Bringiotti, Costantino Zampaletta, Maria Carlotta Sacchi, Lorenzo Ridola, Alessandra Spagnoli, Sabrina Berardi, Angelo Zullo","doi":"10.20524/aog.2024.0928","DOIUrl":"10.20524/aog.2024.0928","url":null,"abstract":"Background: Data on the potential association between diverticulosis and colonic neoplastic lesions are still controversial. We investigated this issue in subjects who underwent screening colonoscopy.Methods: We reviewed the data of subjects with a positive fecal immunological test who underwent a first colonoscopy in the national colorectal screening program. Endoscopic and histological reports were evaluated, using both univariate and multivariate analyses to search for an association between diverticulosis and colonic neoplastic lesions.Results: Data from 5050 subjects (males: 52.2%; mean age: 61.7±6.5 years) observed in the 7 participating centers were considered. Diverticula were found in 2176 (43.1%) cases; at least 1 adenoma was detected in 2277 (45.1%) patients, at least 1 advanced adenoma in 842 (16.7%); and cancer was diagnosed in 159 (3.1%) cases. By univariate analysis, the prevalence of adenomas in patients with diverticula (46.7%, 95% confidence interval [CI] 44.6-48.8%) was significantly higher than in controls (43.8%, 95%CI 42.1-45.7%; P=0.041), while prevalences of both advanced adenomas (13.8%, 95%CI 16.3-19.5%) and cancers (2.4%, 95%CI 1.7-3.1% vs. 3.7%, 95%CI 3.1-4.4%) were lower. By multivariate analysis, only male sex (odds ratio [OR] range: 1.54-2.05) and age (OR range: 1.03-1.05) were found to be independent variables associated with different neoplastic lesions in the colon, whilst diverticulosis was not.Conclusion: This large, multicenter study found no significant association between diverticulosis and neoplastic lesions in subjects who underwent screening colonoscopy.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"68-71"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The treatment interventions and targets of cancer cachexia research during the past decade: a systematic review of the literature. 近十年来癌症恶病质研究的治疗干预和目标：文献系统综述。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-10-20 DOI: 10.20524/aog.2024.0918

Panagiotis Filis, Dimitrios Peschos, Yannis V Simos, Nikolaos Filis, Christianna Zachariou, Dimitrios Stagikas, Konstantinos I Tsamis

{"title":"The treatment interventions and targets of cancer cachexia research during the past decade: a systematic review of the literature.","authors":"Panagiotis Filis, Dimitrios Peschos, Yannis V Simos, Nikolaos Filis, Christianna Zachariou, Dimitrios Stagikas, Konstantinos I Tsamis","doi":"10.20524/aog.2024.0918","DOIUrl":"10.20524/aog.2024.0918","url":null,"abstract":"Background: Cachexia is a detrimental multifactorial syndrome that has been strongly associated with cancer. A growing body of data concerning its management is being generated from the ongoing advances of experimental cancer cachexia research. This study aimed to delineate the broad landscape of cancer cachexia research, by comprehensively presenting the treatment interventions and targets of cancer cachexia during the past decade.Methods: A systematic literature search was performed in Medline and Scopus databases from January to April 2023. Articles were considered eligible if they described any type of intervention in tumor-bearing rodents to study the effect on prevention or treatment of cancer cachexia. The corresponding signaling and metabolic pathways that were targeted by these interventions were documented.Results: A total of 271 articles were considered eligible for our study. Of these, 176 studies pertained to pharmaceutical interventions with 100 corresponding targets, 58 studies pertained to nutritional interventions with 60 corresponding targets, and 37 studies pertained to exercise interventions with 60 corresponding targets.Conclusions: The continuous evolution of cancer cachexia research has provided a plethora of disease targets and corresponding treatment interventions. Moving forward, the available management strategies should be refined and clinical research should efficiently capitalize on the robust experimental evidence.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"85-92"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Simethicone with or without N-acetylcysteine as premedication in esophagogastroduodenoscopy: a systematic review and meta-analysis. 加或不加n -乙酰半胱氨酸的西甲硅氧烷作为食管胃十二指肠镜检查前用药：一项系统回顾和荟萃分析。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.20524/aog.2024.0930

Caroline Tanadi, Fegita Beatrix Pajala, Yehuda Tri Nugroho Supranoto, Kevin Tandarto, Maureen Miracle Stella, Randy Adiwinata, Paulus Simadibrata, Marcellus Simadibrata

{"title":"Simethicone with or without N-acetylcysteine as premedication in esophagogastroduodenoscopy: a systematic review and meta-analysis.","authors":"Caroline Tanadi, Fegita Beatrix Pajala, Yehuda Tri Nugroho Supranoto, Kevin Tandarto, Maureen Miracle Stella, Randy Adiwinata, Paulus Simadibrata, Marcellus Simadibrata","doi":"10.20524/aog.2024.0930","DOIUrl":"10.20524/aog.2024.0930","url":null,"abstract":"Background: The impairment of gastrointestinal mucosa visibility during esophagogastroduodenoscopy (EGD), due to the presence of foam and bubbles, may lead to reduced quality in the EGD results. The combination of simethicone, a defoaming agent, along with N-acetylcysteine (NAC), which has mucolytic properties, has been proposed to improve the visibility of the mucosa. This study aimed to evaluate the effectiveness of pre-procedural administration of simethicone and N-acetylcysteine in improving mucosal visibility, procedure time and mucosal cleansing volume needed during EGD.Methods: We conducted a comprehensive literature search from inception to November 23, 2023, in PubMed, CENTRAL, ProQuest, SAGE, and JSTOR. We included randomized clinical trials that investigated the effects of simethicone with or without NAC as premedication in EGD. For the quantitative analysis, standardized mean difference (SMD) was used to assess continuous outcomes and risk ratio for dichotomous outcomes. The Cochrane risk of bias 2 tool was used to evaluate the risk of bias.Results: This meta-analysis comprised a total of 20 studies and found that simethicone with or without NAC improved mucosal visibility compared with control (SMD -1.27, 95% confidence interval [CI] -1.74 to -0.81, P<0.001). The combination of simethicone and NAC was significantly better than simethicone alone (SMD -0.68, 95%CI -1.08 to -0.28, P=0.001). Simethicone with or without NAC also shortened the procedure time compared to control (MD -1.40, 95%CI -2.67 to -0.12, P=0.03). The risk of bias was low with a moderate grade of certainty.Conclusion: The administration of simethicone with or without NAC may improve EGD quality.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"28-40"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal cancer incidence after lung transplantation in sarcoidosis patients. 结节病患者肺移植后胃肠道肿瘤的发病率。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.20524/aog.2024.0932

Graham Saeed, Tierra Sanders, Dmitry Tumin, Ogugua N Obi, Stanley Oghoghorie, Hassam Ali, Douglas G Adler

{"title":"Gastrointestinal cancer incidence after lung transplantation in sarcoidosis patients.","authors":"Graham Saeed, Tierra Sanders, Dmitry Tumin, Ogugua N Obi, Stanley Oghoghorie, Hassam Ali, Douglas G Adler","doi":"10.20524/aog.2024.0932","DOIUrl":"10.20524/aog.2024.0932","url":null,"abstract":"Background: The risk of gastrointestinal (GI) cancer after lung transplantation (LTx) in sarcoidosis patients is not well defined. Given the cancer risks linked to sarcoidosis and organ transplantation, this study investigated the incidence of GI de novo malignancies (DNM), comparing LTx recipients with sarcoidosis or idiopathic pulmonary fibrosis (IPF).Methods: We analyzed data from the United Network for Organ Sharing registry, including adults with sarcoidosis or IPF who underwent LTx between May 2005 and December 2018. The primary outcome was the incidence of GI DNM by March 2023.Results: Of 7996 lung transplant recipients, 108 (1.35%) developed GI malignancies post-transplantation. Among these, 662 patients (9%) had sarcoidosis and 7334 (91%) had IPF. Sarcoidosis patients showed a non-significant trend toward a higher risk of GI malignancies compared to those with IPF (subhazard ratio 1.72, 95% confidence interval 0.90-3.29; P=0.099), with no observed difference in the risk of non-GI cancers.Conclusions: The overall incidence of GI DNM following LTx is low, and sarcoidosis does not appear to increase the risk of GI cancers compared to IPF. This finding suggests that enhanced GI cancer screening beyond standard guidelines may not be warranted in this population, allowing for targeted surveillance of more prevalent malignancies in sarcoidosis patients post-LTx.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"80-84"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical features and outcomes of total pancreatic lipomatosis with chronic pancreatitis: a case series. 慢性胰腺炎合并全胰脂肪瘤病的临床特征和预后：一个病例系列。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.20524/aog.2025.0939

Surinder Singh Rana, Sanish Ancil, Sachin Hosahally Jayanna, Mandeep Kang, Rajesh Gupta

{"title":"Clinical features and outcomes of total pancreatic lipomatosis with chronic pancreatitis: a case series.","authors":"Surinder Singh Rana, Sanish Ancil, Sachin Hosahally Jayanna, Mandeep Kang, Rajesh Gupta","doi":"10.20524/aog.2025.0939","DOIUrl":"10.20524/aog.2025.0939","url":null,"abstract":"Background: Fatty changes in the pancreas are common, whereas total pancreatic lipomatosis (PL) is rare. Commonly associated with various components of metabolic syndrome and metabolic-associated steatotic liver disease, total PL can have various etiologies and can manifest with severe pancreatic exocrine insufficiency.Method: We retrospectively analysed the clinical profile and management outcomes of 8 patients (mean age: 37.1 years; 5 male) with total PL seen at a tertiary care center over the last 15 years.Results: All patients presented with abdominal pain and had coexistent chronic pancreatitis, while 5/8 (62%) patients had metabolic syndrome. None of the patients had a history of acute pancreatitis or congenital syndromes, nor developed pancreatic carcinoma in the follow up. Seven (87%) patients had pancreatic ductal dilatation and calcification. All patients had pancreatic exocrine insufficiency, while 5/8 (52%) patients had endocrine insufficiency. Six (75%) patients were successfully managed with pancreatic endotherapy.Conclusions: Pancreatic endotherapy is safe and effective in the treatment of abdominal pain in patients who have chronic pancreatitis with total PL. These patients have a high frequency of pancreatic exocrine as well as endocrine insufficiency.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"100-104"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Authors' reply. 作者回复。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-13 DOI: 10.20524/aog.2024.0938

Thanathip Suenghataiphorn, Pojsakorn Danpanichkul, Tuntanut Lohawatcharagul

引用次数: 0

Diagnostic approach to patients with suspected motility disorders: one size does not fit all. 疑似运动障碍患者的诊断方法：一种方法不适合所有患者。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-23 DOI: 10.20524/aog.2025.0941

Theodoros Voulgaris, Theodoros Alexopoulos, Jiannis Vlachogiannakos, Dimitrios Kamberoglou, George Papatheodoridis, George Karamanolis

{"title":"Diagnostic approach to patients with suspected motility disorders: one size does not fit all.","authors":"Theodoros Voulgaris, Theodoros Alexopoulos, Jiannis Vlachogiannakos, Dimitrios Kamberoglou, George Papatheodoridis, George Karamanolis","doi":"10.20524/aog.2025.0941","DOIUrl":"10.20524/aog.2025.0941","url":null,"abstract":"Background: Dysphagia and retrosternal chest pain are considered typical manifestations of major esophageal motility disorders (mEMD). High-resolution manometry (HRM) is the gold standard for mEMD diagnosis, while endoscopy and barium swallow are ancillary tools. We aimed to investigate the frequency of mEMD among patients referred for HRM with typical compared to non-typical symptoms. We also evaluated endoscopic and barium swallow data from patients with mEMD who underwent HRM.Methods: We retrospectively collected epidemiological, endoscopic, barium swallow, and HRM data from 302 patients. Atypical symptoms were considered to be heartburn, regurgitation, globus, oropharyngeal dysphagia, and epigastric pain.Results: The main referral symptoms were: esophageal dysphagia, 58.3%; chest pain, 13.7%; heartburn, 8.9%; regurgitation, 8.3%; and globus/oropharyngeal dysphagia/epigastric pain, 10.8%. A diagnosis of mEMD was more common when typical symptoms existed (69.9% vs. 15.4%, P<0.001). The majority of patients with mEMD in HRM, independently of their symptoms, had an abnormal barium study (typical: 94.8% vs. non-typical: 100%, P=0.633), while compatible endoscopic data tended to be observed more frequently among patients with typical symptoms (69.1% vs. 40%, P=0.057). An HRM diagnosis of mEMD among patients with compatible findings from either barium swallow or endoscopic examination was statistically more frequent among patients with typical symptoms (92.4% vs. 52.6%, P<0.001).Conclusions: More than half of patients referred for HRM will be diagnosed with mEMD, at a higher rate when typical symptoms are reported. A lack of compatible endoscopic and barium swallow findings, in the absence of typical symptoms, makes the diagnosis of mEMD almost impossible.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"12-19"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of pericarditis on cardiovascular complications and healthcare utilization in patients with inflammatory bowel disease: a National Inpatient Sample study. 心包炎对炎症性肠病患者心血管并发症和医疗保健利用的影响：一项全国住院患者样本研究

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.20524/aog.2024.0931

Ayushi Garg, Rohan Menon, Ajit Brar, Hunza Chaudhary, Aalam Sohal, Avneet Kaur, Vijaywant Singh Brar

{"title":"Impact of pericarditis on cardiovascular complications and healthcare utilization in patients with inflammatory bowel disease: a National Inpatient Sample study.","authors":"Ayushi Garg, Rohan Menon, Ajit Brar, Hunza Chaudhary, Aalam Sohal, Avneet Kaur, Vijaywant Singh Brar","doi":"10.20524/aog.2024.0931","DOIUrl":"10.20524/aog.2024.0931","url":null,"abstract":"Background: Inflammatory bowel disease (IBD), which affects over 2.3 million people in the USA, involves chronic gut inflammation and can lead to cardiovascular complications, including pericarditis. Whether pericarditis in IBD patients is caused by medication, or by the disease itself, remains unclear. Our study aimed to determine the prevalence of pericarditis in IBD and its impact on cardiac complications, outcomes and resource utilization.Methods: NIS data were obtained for IBD patients from 2016-2020. Outcomes were assessed using multivariate logistic regression, adjusting for demographics, hospital characteristics, comorbidities, and IBD etiology.Results: In our study of 1.52 million IBD patients, 0.6% had pericarditis, of whom a majority were women (54.1%) and white (76.3%), over 65 years old (43.1%), enrolled in Medicare (51.7%), and living in urban areas (96.3%). Adjusting for confounding factors, IBD patients with pericarditis had higher odds of cardiac arrest (adjusted odds ratio [aOR] 2.73, 95% confidence interval [CI] 1.90-3.91), cardiogenic shock (aOR 6.42, 95%CI 4.77-8.64), and ventricular arrhythmia (aOR 2.13, 95%CI 1.63-2.78 (P<0.001 for all).Conclusions: Our study found that pericarditis, though rare at 0.6%, significantly impacts cardiovascular health and healthcare utilization in IBD patients, with higher prevalence of pericarditis in older individuals, females, and those with comorbidities such as diabetes, hypertension or chronic kidney disease highlighting the need for further research to enhance therapeutic approaches and patient care.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"51-59"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Landscape of B lymphocytes and plasma cells in digestive tract carcinomas. 消化道癌中B淋巴细胞和浆细胞的影像学观察。

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.20524/aog.2024.0936

Konstantina Dimopoulou, Dina Tiniakos, Nikolaos Arkadopoulos, Periklis G Foukas

引用次数: 0

Immune checkpoint inhibitor-associated gastrointestinal adverse events in patients with colorectal cancer. 结直肠癌患者免疫检查点抑制剂相关胃肠道不良事件

IF 2.1

Annals of Gastroenterology Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.20524/aog.2024.0935

Antonio Pizuorno Machado, Saltenat Moghaddam Adames, Malek Shatila, Parvir Aujla, Ryan Huey, Yinghong Wang, Anusha Thomas

{"title":"Immune checkpoint inhibitor-associated gastrointestinal adverse events in patients with colorectal cancer.","authors":"Antonio Pizuorno Machado, Saltenat Moghaddam Adames, Malek Shatila, Parvir Aujla, Ryan Huey, Yinghong Wang, Anusha Thomas","doi":"10.20524/aog.2024.0935","DOIUrl":"10.20524/aog.2024.0935","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICI) target microsatellite instability-high (MSI-H) tumors with success. The incidence and characteristics of ICI-related colitis (IMC) in patients with MSI-H colorectal cancers (CRC) are unclear.Methods: We performed a retrospective analysis of adult patients with CRC who received ICI between June 1, 2014, and December 31, 2022, including data on IMC observed up to 3 months after the last dose of ICI. Patients' demographics, oncologic profile, endoscopic features, treatment and clinical outcomes were evaluated.Results: Of 474 patients with CRC receiving ICI during our study period, 18 developed IMC (3.8%). The majority were Caucasian (88.8%), male (61.1%), and their median age was 69.5 years. Of these patients, 50% received combination therapy with anti-PD-1/L1 and CTLA-4; 66.6% had MSI-H colorectal cancer, 11.1% had a second cancer-melanoma, while 61.2% and 66.7% had grade 1-2 colitis and diarrhea respectively. Endoscopic evaluation was used in 5 patients, of whom 2 had ulcerative inflammation necessitating selective immunosuppressive therapy with biologics. Therapy was withheld in 61.1% because of toxicity; 41.4% and 5.8% were noted to have median Common Terminology Criteria for Adverse Events grade 2 liver and pancreas toxicity respectively. The majority of our cohort received steroid therapy.Conclusions: The lower severity of IMC, compared to toxicity in other ICI-treated cancers, may be influenced by the tumor microenvironment in MSI-H colorectal cancer after ICI exposure. Larger prospective studies are necessary to determine the role of tumor biology and the gut microbiome in the disease profile and severity of IMC.","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 1","pages":"72-79"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0